Viridian Therapeutics, Inc.
0K1R.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.11B
Close$
$-10.01
154.1% downside
Current Fair Value
154.1% downsideOvervalued by 154.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.11 Billion |
|---|---|
| Enterprise Value | $2.19 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.32 |
| Beta | 0.94 |
| Outstanding Shares | 107,884,104 |
Return
| Return on Equity | -58.45% |
|---|---|
| Return on Assets | -35.27% |
| Return on Invested Capital | -37.63% |
Valuation & Multiples
| P/E Ratio | -5.29 |
|---|---|
| PEG | -20.18 |
| Price to Sales | - |
| Price to Book Ratio | 3.09 |
| Enterprise Value to Revenue | 30.81 |
| Enterprise Value to EBIT | -5.63 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.37 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-1.03
Average shareholder expectationRevenue Estimate
$56,364
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.97
Average shareholder expectationRevenue Estimate
$4.58 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Viridian Therapeutics Inc
27 employees
CEO: William Marshall Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R mono...